SCHOTT Pharma AG & Co. KGaA 1SXP
XETR · Germany · Health Technology
€24.35-0.60 (-2.40%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
SCHOTT Group's updated climate targets, including the business scope of SCHOTT Pharma, have been validated by the Science Based Targets initiative (SBTi). The company continues to focus on sourcing Energy Attribute Certificates from renewable ene...
Schott Pharma AG & CO KGaA (WBO:1SXP) reports 8.3% constant-currency revenue growth in Q3, lifts full-year outlook, and secures a key take-or-pay glass syringe agreement.
LEBANON, Pa., June 03, 2026--SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs – from biologics and other complex injectable therapies to vaccines and emergency room medications. The new capabilities feature state-of-the-art technology for efficient manufacturing and optimized output. The over 60 million USD investment was largely fu
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.